Entero Healthcare Solutions Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company reported its financial performance, along with the approval of the grant of 49,712 employee stock options under its existing plan. The board also noted the financial results and approved various related disclosures.
Entero Healthcare Announces Financial Results and Employee Stock Options
Entero Healthcare Solutions Limited has disclosed its unaudited financial results for the second quarter and the half year ended September 30, 2026. The company’s Board of Directors, during their meeting on November 4, 2026, considered and approved these financial statements, which include both standalone and consolidated figures.
Key Financial Highlights
The disclosed financial results, presented as Annexure-A, cover the period ending September 30, 2026. Alongside the financial performance, the Board of Directors also noted the grant of 49,712 employee stock options. These options are part of the “Entero Employee Stock Option Plan 2023” and were approved following the recommendation of the Nomination & Remuneration Committee. The grant specifies an exercise price of INR 804 per option.
Disclosure and Trading Window
Details pertaining to these stock options, as required by SEBI regulations, are provided in Annexure-B. Furthermore, the company has informed stakeholders that the trading window for dealing in the company’s securities will reopen 48 hours after the disclosure of these financial results. This information is also accessible on the company’s website, www.enterohealthcare.com.
Standalone Financial Performance Snapshot (Q2 FY27 vs. Q2 FY26)
For the quarter ended September 30, 2026, Entero Healthcare reported Total Income of INR 1,366.53 million, a significant increase from INR 1,064.11 million in the same quarter of the previous year. Profit before tax stood at INR 243.19 million, compared to INR 46.05 million in Q2 FY26. The Profit for the period after tax was INR 191.44 million, up from INR 34.57 million in the prior year’s quarter.
Consolidated Financial Performance Snapshot (Q2 FY27 vs. Q2 FY26)
On a consolidated basis, Total Income for the quarter ended September 30, 2026, reached INR 20,910.67 million, an increase from INR 15,757.39 million in Q2 FY26. Profit before tax was INR 783.87 million, compared to INR 446.25 million in the previous year’s quarter. The consolidated Profit for the period after tax amounted to INR 607.42 million, up from INR 366.00 million in Q2 FY26.
Half-Yearly Performance (H1 FY27 vs. H1 FY26)
For the half-year ended September 30, 2026, standalone Total Income was INR 2,430.64 million, versus INR 2,130.86 million in H1 FY26. Standalone Profit for the period after tax was INR 226.01 million, compared to INR 126.53 million in the previous year’s half-year. Consolidated Total Income for H1 FY27 stood at INR 40,345.69 million, up from INR 29,853.83 million in H1 FY26. Consolidated Profit for the period after tax was INR 1,127.93 million, compared to INR 668.32 million in H1 FY26.
Employee Stock Option Grant Details
The grant of 49,712 options under the “Entero Employee Stock Option Plan 2023” is detailed in Annexure-B. These options are granted to eligible employees at an exercise price of INR 804 per option. The vesting period ranges from a minimum of one year to a maximum of four years from the grant date, with an exercise period of eight years from the vesting date. The scheme complies with SEBI (Share Based Employee Benefits) Regulations, 2021.
Source: BSE
